In retrospect, the therapeutic potential of immunoglobulins was first demonstrated by von Behring and Kitasato in the late nineteenth century by protecting mice from the lethal effects caused by tetanus and diphtheria toxin via injection of a hyperimmune serum generated in rabbits. Even today, hyperimmune sera generated from human donors with high serum titers against a certain pathogen are still in use as a means of providing passive protection. More importantly, therapeutic antibodies specific for malignant or autoreactive cells have become included in the standard of care in diseases such as breast cancer and malignant lymphoma. Despite this clinical success, we are only at the beginning of understanding the precise molecular and cellular pathways responsible for immunoglobulin G (IgG) activity in vivo. Since then, an enormous amount of information about the mechanism of IgG activity has been obtained in various model systems. The aim of this review is to provide a comprehensive overview of our current understanding of how IgG antibodies mediate their activity in vivo and how we can use this knowledge to enhance the activity of therapeutic antibodies or block the proinflammatory and tissue pathology inducing activity of autoantibodies. 1. Introduction Antibodies of the IgG isotype are an essential component of our armament against pathogenic microorganisms. IgG binding to invading microorganisms can block their binding to cellular receptors providing the basis for the so-called “sterile” immunity, which protects us from reinfection with highly cytopathic viruses such as influenza. On the other hand, IgG binding to bacteria makes them more visible for phagocytic cells, allowing removing them or their toxic products from the body. Apart from this protective function, autoantibodies directed against self-antigens are a major cause of tissue inflammation or removal of platelets and red blood cells resulting in autoimmune diseases such as systemic lupus erythematosus (SLE), chronic inflammatory demyelinating polyneuropathy (CIDP), skin blistering diseases, immunothrombocytopenia (ITP), and autoimmune hemolytic anemia (AIHA) [1–3]. Finally the potent cytotoxic function of IgG molecules having the capacity to find and destroy virtually any cell within the body is used therapeutically in the form of tumor-specific cytotoxic antibodies, exemplified by CD20, Her2/Neu, or CD52 specific antibodies [4, 5]. A detailed understanding of the molecular and cellular mechanisms underlying IgG activity are therefore of great importance as this may allow (1) improving
References
[1]
P. M. Hogarth and G. A. Pietersz, “Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond,” Nature Reviews Drug Discovery, vol. 11, no. 4, pp. 311–331, 2012.
[2]
F. Nimmerjahn and J. V. Ravetch, “FcgammaRs in health and disease,” Current Topics in Microbiology and Immunology, vol. 350, pp. 105–125, 2011.
[3]
T. Takai, “Roles of Fc receptors in autoimmunity,” Nature Reviews Immunology, vol. 2, no. 8, pp. 580–592, 2002.
[4]
P. J. Carter, “Potent antibody therapeutics by design,” Nature Reviews Immunology, vol. 6, no. 5, pp. 343–357, 2006.
[5]
R. Jefferis, “Antibody therapeutics: isotype and glycoform selection,” Expert Opinion on Biological Therapy, vol. 7, no. 9, pp. 1401–1413, 2007.
[6]
I. Schwab and F. Nimmerjahn, “Intravenous immunoglobulin therapy: how does IgG modulate the immune system?” Nature Reviews Immunology, vol. 13, no. 3, pp. 176–189, 2013.
[7]
J. Bayry, V. S. Negi, and S. V. Kaveri, “Intravenous immunoglobulin therapy in rheumatic diseases,” Nature Reviews Rheumatology, vol. 7, no. 6, pp. 349–359, 2011.
[8]
M. C. Carroll, “The complement system in regulation of adaptive immunity,” Nature Immunology, vol. 5, no. 10, pp. 981–986, 2004.
[9]
R. Malhotra, M. R. Wormald, P. M. Rudd, P. B. Fischer, R. A. Dwek, and R. B. Sim, “Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein,” Nature Medicine, vol. 1, no. 3, pp. 237–243, 1995.
[10]
F. Nimmerjahn, R. M. Anthony, and J. V. Ravetch, “Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 20, pp. 8433–8437, 2007.
[11]
J. N. Arnold, M. R. Wormald, R. B. Sim, P. M. Rudd, and R. A. Dwek, “The impact of glycosylation on the biological function and structure of human immunoglobulins,” Annual Review of Immunology, vol. 25, pp. 21–50, 2007.
[12]
M. Da?ron and R. Lesourne, “Negative signaling in Fc receptor complexes,” Advances in Immunology, vol. 89, pp. 39–86, 2006.
[13]
F. Nimmerjahn and J. V. Ravetch, “Fcγ receptors as regulators of immune responses,” Nature Reviews Immunology, vol. 8, no. 1, pp. 34–47, 2008.
[14]
S. Bolland and J. V. Ravetch, “Inhibitory pathways triggered by itim-containing receptors,” Advances in Immunology, no. 72, pp. 149–177, 1999.
[15]
K. G. Smith and M. R. Clatworthy, “FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications,” Nature Reviews Immunology, vol. 10, no. 5, pp. 328–343, 2010.
[16]
J. V. Ravetch and L. L. Lanier, “Immune inhibitory receptors,” Science, vol. 290, no. 5489, pp. 84–89, 2000.
[17]
F. Nimmerjahn and J. V. Ravetch, “Fcγ receptors: old friends and new family members,” Immunity, vol. 24, no. 1, pp. 19–28, 2006.
[18]
A. Lux, X. Yu, C. N. Scanlan, and F. Nimmerjahn, “Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs,” The Journal of Immunology, vol. 190, no. 8, pp. 4315–4323, 2013.
[19]
P. M. Hogarth, “Fc receptors are major mediators of antibody based inflammation in autoimmunity,” Current Opinion in Immunology, vol. 14, no. 6, pp. 798–802, 2002.
[20]
A. Lux and F. Nimmerjahn, “Of mice and men: the need for humanized mouse models to study human IgG activity in vivo,” Journal of Clinical Immunology, vol. 33, supplement 1, pp. S4–S8, 2013.
[21]
B. Lehmann, I. Schwab, S. Bhm, A. Lux, M. Biburger, and F. Nimmerjahn, “FcγRIIB: a modulator of cell activation and humoral tolerance,” Expert Review of Clinical Immunology, vol. 8, no. 3, pp. 243–254, 2012.
[22]
S. Bolland and J. V. Ravetch, “Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis,” Immunity, vol. 13, no. 2, pp. 277–285, 2000.
[23]
S. Bolland, Y.-S. Yim, K. Tus, E. K. Wakeland, and J. V. Ravetch, “Genetic modifiers of systemic lupus erythematosus in FcγRIIB-/- mice,” Journal of Experimental Medicine, vol. 195, no. 9, pp. 1167–1174, 2002.
[24]
P. Boross, V. L. Arandhara, J. Martin-Ramirez et al., “The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility,” Journal of Immunology, vol. 187, no. 3, pp. 1304–1313, 2011.
[25]
H. Fukuyama, F. Nimmerjahn, and J. V. Ravetch, “The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells,” Nature Immunology, vol. 6, no. 1, pp. 99–106, 2005.
[26]
M. Espeli, M. R. Clatworthy, S. Bokers, et al., “Analysis of a wild mouse promoter variant reveals a novel role for FcgammaRIIb in the control of the germinal center and autoimmunity,” The Journal of Experimental Medicine, vol. 209, no. 12, pp. 2307–2319, 2012.
[27]
A. Baerenwaldt, A. Lux, H. Danzer, et al., “Fcgamma receptor IIB, (FcgammaRIIB) maintains humoral tolerance in the human immune system in vivo,” Proceedings of the National Academy of Sciences of USA, vol. 108, pp. 18772–18777, 2011.
[28]
M. R. Clatworthy, L. Willcocks, B. Urban et al., “Systemic lupus erythematosus-associated defects in the inhibitory receptor FcγRIIb reduce susceptibility to malaria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 17, pp. 7169–7174, 2007.
[29]
R. A. Floto, M. R. Clatworthy, K. R. Heilbronn et al., “Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts,” Nature Medicine, vol. 11, no. 10, pp. 1056–1058, 2005.
[30]
H. Kono, C. Kyogoku, T. Suzuki et al., “FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling,” Human Molecular Genetics, vol. 14, no. 19, pp. 2881–2892, 2005.
[31]
B. Nieswandt, B. Echtenacher, F.-P. Wachs et al., “Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice,” Blood, vol. 94, no. 2, pp. 684–693, 1999.
[32]
B. Nieswandt, W. Bergmeier, V. Schulte et al., “Targeting of platelet integrin αIIbβ3 determines systemic reaction and bleeding in murine thrombocytopenia regulated by activating and inhibitory FcγR,” International Immunology, vol. 15, no. 3, pp. 341–349, 2003.
[33]
M. Biburger, S. Aschermann, I. Schwab et al., “Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo,” Immunity, vol. 35, no. 6, pp. 932–944, 2011.
[34]
B. Nieswandt, W. Bergmeier, K. Rackebrandt, J. Engelbert Gessner, and H. Zirngibl, “Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice,” Blood, vol. 96, no. 7, pp. 2520–2527, 2000.
[35]
S. B. Clarkson, J. B. Bussel, and R. P. Kimberly, “Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody,” The New England Journal of Medicine, vol. 314, no. 19, pp. 1236–1239, 1986.
[36]
A. Samuelsson, T. L. Towers, and J. V. Ravetch, “Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor,” Science, vol. 291, no. 5503, pp. 484–486, 2001.
[37]
T. Takai, M. Li, D. Sylvestre, R. Clynes, and J. V. Ravetch, “FcR γ chain deletion results in pleiotrophic effector cell defects,” Cell, vol. 76, no. 3, pp. 519–529, 1994.
[38]
M. C. Carroll, “The role of complement and complement receptors in induction and regulation of immunity,” Annual Review of Immunology, vol. 16, pp. 545–568, 1998.
[39]
F. Nimmerjahn and J. V. Ravetch, “Analyzing antibody-Fc-receptor interactions,” Methods in Molecular Biology, vol. 415, pp. 151–162, 2008.
[40]
R. Clynes and J. V. Ravetch, “Cytotoxic antibodies trigger inflammation through Fc receptors,” Immunity, vol. 3, no. 1, pp. 21–26, 1995.
[41]
H. Mizutani, R. W. Engelman, Y. Kurata, S. Ikehara, and R. A. Good, “Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW x BXSB)F1 mice,” Blood, vol. 82, no. 3, pp. 837–844, 1993.
[42]
D. Sylvestre, R. Clynes, M. Ma, H. Warren, M. C. Carroll, and J. V. Ravetch, “Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice,” Journal of Experimental Medicine, vol. 184, no. 6, pp. 2385–2392, 1996.
[43]
F. Nimmerjahn, P. Bruhns, K. Horiuchi, and J. V. Ravetch, “FcγRIV: a novel FcR with distinct IgG subclass specificity,” Immunity, vol. 23, no. 1, pp. 41–51, 2005.
[44]
F. Nimmerjahn and J. V. Ravetch, “Immunology: divergent immunoglobulin G subclass activity through selective Fc receptor binding,” Science, vol. 310, no. 5753, pp. 1510–1512, 2005.
[45]
F. Nimmerjahn, A. Lux, H. Albert et al., “FcYγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 45, pp. 19396–19401, 2010.
[46]
L. Fossati-Jimack, A. Ioan-Facsinay, L. Reininger et al., “Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III,” Journal of Experimental Medicine, vol. 191, no. 8, pp. 1293–1302, 2000.
[47]
J. Uchida, Y. Hamaguchi, J. A. Oliver et al., “The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy,” Journal of Experimental Medicine, vol. 199, no. 12, pp. 1659–1669, 2004.
[48]
R. M. Anthony, F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson, and J. V. Ravetch, “Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc,” Science, vol. 320, no. 5874, pp. 373–376, 2008.
[49]
P. Bruhns, A. Samuelsson, J. W. Pollard, and J. V. Ravetch, “Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease,” Immunity, vol. 18, no. 4, pp. 573–581, 2003.
[50]
Y. Kaneko, F. Nimmerjahn, M. P. Madaio, and J. V. Ravetch, “Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors,” Journal of Experimental Medicine, vol. 203, no. 3, pp. 789–797, 2006.
[51]
Y. Kaneko, F. Nimmerjahn, and J. V. Ravetch, “Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation,” Science, vol. 313, no. 5787, pp. 670–673, 2006.
[52]
A. R. Crow, S. Song, J. Freedman et al., “IVIG-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity,” Blood, vol. 102, no. 2, pp. 558–560, 2003.
[53]
H.-S. Huang, D.-S. Sun, T.-S. Lien, and H.-H. Chang, “Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice,” Blood, vol. 116, no. 23, pp. 5002–5009, 2010.
[54]
R. M. Anthony, T. Kobayashi, F. Wermeling, and J. V. Ravetch, “Intravenous gammaglobulin suppresses inflammation through a novel T H 2 pathway,” Nature, vol. 475, no. 7354, pp. 110–114, 2011.
[55]
R. M. Anthony, F. Wermeling, M. C. I. Karlsson, and J. V. Ravetch, “Identification of a receptor required for the anti-inflammatory activity of IVIG,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 50, pp. 19571–19578, 2008.
[56]
R. M. Anthony and J. V. Ravetch, “A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs,” Journal of Clinical Immunology, vol. 30, no. 1, pp. S9–S14, 2010.
[57]
V.-S. Negi, S. Elluru, S. Sibéril et al., “Intravenous immunoglobulin: an update on the clinical use and mechanisms of action,” Journal of Clinical Immunology, vol. 27, no. 3, pp. 233–245, 2007.
[58]
B. Tackenberg, F. Nimmerjahn, and J. D. Lünemann, “Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy,” Journal of Clinical Immunology, vol. 30, no. 1, pp. S65–S69, 2010.
[59]
A. Podolanczuk, A. H. Lazarus, A. R. Crow, E. Grossbard, and J. B. Bussel, “Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk,” Blood, vol. 113, no. 14, pp. 3154–3160, 2009.
[60]
J. Bussel, “Treatment of immune thrombocytopenic purpura in adults,” Seminars in Hematology, vol. 43, no. 5, pp. S3–S10, 2006.
[61]
A. P. Deyns, M. G. Lotter, and P. N. Badenhorst, “Kinetics, distribution and sites of destruction of 111indium-labelled human platelets,” British Journal of Haematology, vol. 44, no. 2, pp. 269–280, 1980.
[62]
H. Mizutani, T. Furubayashi, H. Kashiwagi et al., “Effects of splenectomy on immune thrombocytopenic purpura in (NZW x BXSB) F1 mice: analyses of platelet kinetics and anti-platelet antibody production,” Thrombosis and Haemostasis, vol. 67, no. 5, pp. 563–566, 1992.
[63]
K. G. Schmidt and J. W. Rasmussen, “Kinetics and distribution in vivo of 111In-labelled autologous platelets in idiopathic thrombocytopenic purpura,” Scandinavian Journal of Haematology, vol. 34, no. 1, pp. 47–56, 1985.
[64]
J. R. Stratton, P. J. Ballem, T. Gernsheimer, M. Cerqueira, and S. J. Slichter, “Platelet destruction in autoimmune thrombocytopenic purpura: Kinetics and clearance of indium-111-labeled autologous platelets,” Journal of Nuclear Medicine, vol. 30, no. 5, pp. 629–637, 1989.
[65]
C. Auffray, D. Fogg, M. Garfa et al., “Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior,” Science, vol. 317, no. 5838, pp. 666–670, 2007.
[66]
J. Cros, N. Cagnard, K. Woollard et al., “Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors,” Immunity, vol. 33, no. 3, pp. 375–386, 2010.
[67]
F. Geissmann, M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, and K. Ley, “Development of monocytes, macrophages, and dendritic cells,” Science, vol. 327, no. 5966, pp. 656–661, 2010.
[68]
G. Fingerle-Rowson, M. Angstwurm, R. Andreesen, and H. W. L. Ziegler-Heitbrock, “Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy,” Clinical and Experimental Immunology, vol. 112, no. 3, pp. 501–506, 1998.
[69]
F. Dayyani, K.-U. Beige, M. Frankenberger, M. Mack, T. Berki, and L. Ziegler-Heitbrock, “Mechanism of glucocorticoid-induced depletion of human CD14 +CD16+ monocytes,” Journal of Leukocyte Biology, vol. 74, no. 1, pp. 33–39, 2003.
[70]
G. Fingerle-Rowson, J. Auers, E. Kreuzer, P. Fraunberger, M. Blumenstein, and L. H. W. Ziegler-Heitbrock, “Expansion of CD14+CD16+ monocytes in critically ill cardiac surgery patients,” Inflammation, vol. 22, no. 4, pp. 367–379, 1998.
[71]
M.-L. Santiago-Raber, H. Amano, E. Amano et al., “Fcγ receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice,” Arthritis and Rheumatism, vol. 60, no. 8, pp. 2408–2417, 2009.
[72]
M.-L. Santiago-Raber, L. Baudino, M. Alvarez, N. van Rooijen, F. Nimmerjahn, and S. Izui, “TLR7/9-mediated monocytosis and maturation of Gr-1hi inflammatory monocytes towards Gr-1lo resting monocytes implicated in murine lupus,” Journal of Autoimmunity, vol. 37, no. 3, pp. 171–179, 2011.
[73]
G. G. De Sá Oliveira, S. Izui, C. T. Ravirajan et al., “Diverse antigen specificity of erythrocyte-reactive monoclonal autoantibodies from NZB mice,” Clinical and Experimental Immunology, vol. 105, no. 2, pp. 313–320, 1996.
[74]
S. A. Da Silveira, S. Kikuchi, L. Fossati-Jimack et al., “Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody,” Journal of Experimental Medicine, vol. 195, no. 6, pp. 665–672, 2002.
[75]
L. Baudino, F. Nimmerjahn, S. A. Da Silveira et al., “Differential contribution of three activating IgG Fc receptors (FcγRI, FcγRIII, and FcγRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice,” Journal of Immunology, vol. 180, no. 3, pp. 1948–1953, 2008.
[76]
D. Meyer, G. Schiller, J. Westermann et al., “FcγRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia,” Blood, vol. 92, no. 11, pp. 3997–4002, 1998.
[77]
S. N. Syed, S. Konrad, K. Wiege et al., “Both FcγRIV and FcγRIII are essential receptors mediating type II and type III autoimmune responses via FcRγ-LAT-dependent generation of C5a,” European Journal of Immunology, vol. 39, no. 12, pp. 3343–3356, 2009.
[78]
L. Baudino, F. Nimmerjahn, Y. Shinohara et al., “Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions,” Journal of Immunology, vol. 181, no. 6, pp. 4107–4112, 2008.
[79]
A.-S. Korganow, J. Hong, S. Mangialaio et al., “From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins,” Immunity, vol. 10, no. 4, pp. 451–461, 1999.
[80]
P. A. Monach, P. A. Nigrovic, M. Chen et al., “Neutrophils in a mouse model of autoantibody-mediated arthritis: critical producers of Fc receptor gamma, the receptor for C5a, and lymphocyte function-associated antigen 1,” Arthritis and Rheumatism, vol. 62, no. 3, pp. 753–764, 2010.
[81]
S. Solomon, N. Rajasekaran, E. Jeisy-Walder, S. B. Snapper, and H. Illges, “A crucial role for macrophages in the pathology of K/B × N serum-induced arthritis,” European Journal of Immunology, vol. 35, no. 10, pp. 3064–3073, 2005.
[82]
D. M. Lee, D. S. Friend, M. F. Gurish, C. Benoist, D. Mathis, and M. B. Brenner, “Mast cells: a cellular link between autoantibodies and inflammatory arthritis,” Science, vol. 297, no. 5587, pp. 1689–1692, 2002.
[83]
P. A. Nigrovic, B. A. Binstadt, P. A. Monach et al., “Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 7, pp. 2325–2330, 2007.
[84]
T. B. Feyerabend, A. Weiser, A. Tietz et al., “Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity,” Immunity, vol. 35, no. 5, pp. 832–844, 2011.
[85]
H. Ji, K. Ohmura, U. Mahmood et al., “Arthritis critically dependent on innate immune system players,” Immunity, vol. 16, no. 2, pp. 157–168, 2002.
[86]
B. A. Binstadt, P. R. Patel, H. Alencar et al., “Particularities of the vasculature can promote the organ specificity of autoimmune attack,” Nature Immunology, vol. 7, no. 3, pp. 284–292, 2006.
[87]
M. Seeling, U. Hillenhoff, J. P. David, et al., “Inflammatory monocytes and Fcgamma receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice,” Proceedings of the National Academy of Sciences of USA, vol. 110, no. 26, pp. 10729–10734, 2013.
[88]
G. S. Firestein, “Evolving concepts of rheumatoid arthritis,” Nature, vol. 423, no. 6937, pp. 356–361, 2003.
[89]
I. B. McInnes and G. Schett, “The pathogenesis of rheumatoid arthritis,” The New England Journal of Medicine, vol. 365, no. 23, pp. 2205–2219, 2011.
[90]
E. M?ssner, P. Brünker, S. Moser et al., “Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell—mediated B-cell cytotoxicity,” Blood, vol. 115, no. 22, pp. 4393–4402, 2010.
[91]
S. H. Lim, S. A. Beers, R. R. French, P. W. M. Johnson, M. J. Glennie, and M. S. Cragg, “Anti-CD20 monoclonal antibodies: historical and future perspectives,” Haematologica, vol. 95, no. 1, pp. 135–143, 2010.
[92]
T. A. Barr, P. Shen, S. Brown, et al., “B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells,” The Journal of Experimental Medicine, vol. 209, no. 5, pp. 1001–1010, 2012.
[93]
S. A. Beers, C. H. T. Chan, R. R. French, M. S. Cragg, and M. J. Glennie, “CD20 as a target for therapeutic type i and ii monoclonal antibodies,” Seminars in Hematology, vol. 47, no. 2, pp. 107–114, 2010.
[94]
B. Coiffier, S. Lepretre, L. M. Pedersen et al., “Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A Phase 1-2 Study,” Blood, vol. 111, no. 3, pp. 1094–1100, 2008.
[95]
P. C. Taylor, E. Quattrocchi, S. Mallett, R. Kurrasch, J. Petersen, and D. J. Chang, “Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial,” Annals of the Rheumatic Diseases, vol. 70, no. 12, pp. 2119–2125, 2011.
[96]
J. L. Teeling, R. R. French, M. S. Cragg et al., “Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas,” Blood, vol. 104, no. 6, pp. 1793–1800, 2004.
[97]
M. Usuda, K. Fujimori, N. Koyamada et al., “Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation,” Transplantation, vol. 79, no. 1, pp. 12–16, 2005.
[98]
G. Cartron, L. Dacheux, G. Salles et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγrIIIa gene,” Blood, vol. 99, no. 3, pp. 754–758, 2002.
[99]
W.-K. Weng, D. Czerwinski, J. Timmerman, F. J. Hsu, and R. Levy, “Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype,” Journal of Clinical Oncology, vol. 22, no. 23, pp. 4665–4672, 2004.
[100]
W.-K. Weng and R. Levy, “Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma,” Journal of Clinical Oncology, vol. 21, no. 21, pp. 3940–3947, 2003.
[101]
A. Musolino, N. Naldi, B. Bortesi et al., “Immunoglobulin g fragment c receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer,” Journal of Clinical Oncology, vol. 26, no. 11, pp. 1789–1796, 2008.
[102]
Y. Hamaguchi, Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder, “Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy,” Journal of Experimental Medicine, vol. 203, no. 3, pp. 743–753, 2006.
[103]
S. A. Beers, C. H. T. Chan, S. James et al., “Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation,” Blood, vol. 112, no. 10, pp. 4170–4177, 2008.
[104]
S. A. Beers, R. R. French, H. T. C. Chan et al., “Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection,” Blood, vol. 115, no. 25, pp. 5191–5201, 2010.
[105]
N. Yazawa, Y. Hamaguchi, J. C. Poe, and T. F. Tedder, “Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 42, pp. 15178–15183, 2005.
[106]
E. Racila, B. K. Link, W.-K. Weng et al., “A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma,” Clinical Cancer Research, vol. 14, no. 20, pp. 6697–6703, 2008.
[107]
S. Veeramani, S.-Y. Wang, C. Dahle et al., “Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism,” Blood, vol. 118, no. 12, pp. 3347–3349, 2011.
[108]
S.-Y. Wang, E. Racila, R. P. Taylor, and G. J. Weiner, “NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement,” Blood, vol. 111, no. 3, pp. 1456–1463, 2008.
[109]
S.-Y. Wang, S. Veeramani, E. Racila et al., “Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model,” Blood, vol. 114, no. 26, pp. 5322–5330, 2009.
[110]
S.-Y. Wang and G. Weiner, “Complement and cellular cytotoxicity in antibody therapy of cancer,” Expert Opinion on Biological Therapy, vol. 8, no. 6, pp. 759–768, 2008.
[111]
G. J. Weiner, “Rituximab: mechanism of action,” Seminars in Hematology, vol. 47, no. 2, pp. 115–123, 2010.
[112]
M. Biburger and F. Nimmerjahn, “Low level of FcγRIII expression on murine natural killer cells,” Immunology Letters, vol. 143, no. 1, pp. 53–59, 2012.